drugset / Trial / NCT07470606
Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
Phase 2
Not yet recruiting
108 enrolled
The University of Texas Health Science Center at San Antonio
RandomizedParallel-groupOpen-labelTreatment
Summary
The study investigators are testing to see if patients receiving radiation treatment for brain cancer along with raloxifene plus memantidine take longer to develop memory issues. The study will include anyone over the age of 18 who will be treated with radiation for brain cancer.
Timeline
- Start
- 2026-03
- Primary completion
- 2030-03
- Completion
- 2031-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Raloxifene | Other / unclassified | 120 mg | Oral |
| Background | Memantine | Unknown | 10 mg | Oral |
| Background | Memantine | Unknown | 21 mg | Oral |